Posted by Michael Wonder on 01 Dec 2022
Aurinia announces the Great Britain marketing authorisation of Lupkynis (voclosporin) for the treatment of lupus nephritis
30 November 2022 - MHRA Approval follows European Commission marketing authorisation of Lupkynis to treat adults with active lupus nephritis in 27 European Union member states.
Aurinia Pharmaceuticals announced that the UK MHRA has granted the Great Britain marketing authorisation of Lupkynis (voclosporin) to treat adults with active lupus nephritis, a serious complication of systemic lupus erythematosus.
